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ABSTRACT
Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
widely prescribed for their analgesic, anti-pyretic and 
anti-inflammatory effects. There is no doubt regarding 
their benefits; however the importance of their side 
effects including gastrointestinal complications cannot 
be emphasized enough especially in high risk groups.
Objectives
This study assessed the awareness of general practitioners 
(GPs) working within Maltese health centres of the 
National Institute for Health and Care Excellence 
(NICE) guidelines on the proper prescription of NSAIDs, 
especially the co-prescription of gastroprotective agents 
in high risk groups. 
Method
An online questionnaire based on the NICE guidelines 
on NSAID Prescribing Issues revised in July 2015 was 
distributed to doctors working within health centres 
across Malta.
Results
Trauma was the most popular reason for NSAID 
prescription (75%), with the commonest patient age 
group being that below 45 years of age.  Diclofenac was 
the most popular NSAID choice (55.4%) with COX-2 
inhibitors being the preferred choice for 23.2%.  Most 
doctors were aware of factors that need to be considered 
when initiating NSAIDs, being least aware of liver 
comorbidities and fertility issues.  The majority use 
licensed gastroprotective agents both in drug choice and 
in dose.  More awareness is required on high risk patient 
groups especially patients with arthritis and patients on 
selective serotonin reuptake inhibitors (SSRIs). 
Conclusion
There is room for improvement in awareness on 
proper NSAID use and gastroprotection especially in 
identifying high risk groups, drug interactions and 
choice of gastroprotective agents.  The importance of 
gastroprotection, side effect monitoring, prevention 
of unnecessary chronic NSAID use and promotion of 
coxib use over standard NSAIDs needs to be emphasized 
further especially in high risk groups.
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BACKGROUND
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
among the most widely prescribed medications within 
general practice in the community for a multitude of 
medical conditions. They are mostly prescribed in view 
of their analgesic, anti-pyretic and in higher doses, 
their anti-inflammatory effects. NSAIDs demonstrate 
variable inhibition of both cyclooxygenase-1 and 
cyclooxygenase-2 isoenzymes, both involved in the 
formation of prostaglandins which play an active role in 
inflammatory processes (Neal, 2012).
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Factors to consider when initiating NSAIDs
Contraindications
Alternative treatment
Patient already on NSAID?
Lowest dose & shortest duration for effective treatment
Gastroprotection especially in high risk groups
Side effect monitoring especially in high risk groups
Drug interactions
absolute and relative Contraindications
Hypersensitivity
Low eGFR
Skin reactions and angioedema
Asthma
Heart Failure
Liver fibrosis and cirrhosis
Acute liver failure and severe hepatic impairment 
(North Lewis, 2008)
History of/current treatment for GI problems
IBD
IHD, CVD, PAD
Dehydration especially in diabetics
HT
Women trying to conceive
Hepatitis and cholestasis
Monitoring in high risk patient groups
Blood pressure - especially within 1-2 weeks 
of starting/increasing dose
Renal function - especially within 1-2 weeks 
of starting/increasing dose
Features of heart failure including body weight
Enquire about GI bleeding and fluid retention 
in people with hepatic impairment
Table 1: Table showing the main recommendations highlighted in the NICE guidelines NSAID Prescribing Issues last revised in July 2015
NICE GUIDELINES NSAID PRESCRIBING ISSUES JULY 2015
Licensed PPIs and their doses for gastroprotection
Lansoprazole 15-30mg daily. 
Omeprazole 20mg daily
Esomperazole 20mg daily
Pantoprazole 20mg daily
High risk patient groups  - to consider PPI
Patients on maximum recommended dose
65 years +
History of GI bleeding/perforation
Concomitant aspirin use
Concomitant steroid use
Concomitant SSRI use
Cardiovascular, hepatic, renal impairment
Diabetics
Hypertensives
Osteoarthritis & Rheumatoid arthritis
Chronic low back pain
Heavy smoking or alcohol use
H.pylori infection 
Drug interactions in primary care
Low dose aspirin
ACE inhibitors
Ciclosporin
ARBs
Thiazide type, potassium and loop diuretics
Lithium
Methotrexate
Probenecid
Quinolones
Antidepressants
Anticoagulants
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NSAIDs can be classified as standard (such 
as diclofenac, ibuprofen and naproxen) or COX-2 
inhibitors such as celecoxib and etoricoxib (NICE 
Guidelines NSAID Prescribing Issues, 2015). Whilst 
there is no doubt about the various benefits that can 
be derived from NSAID use, research done throughout 
the years on these drugs has highlighted the importance 
of being aware of possible adverse effects, such as the 
development of cardiovascular and gastrointestinal 
complications, the latter through mucosal injury 
and COX-1 derived prostaglandin inhibition. This 
should be taken into consideration in all patients but 
especially in high risk patient groups, most notably 
individuals with a past history of peptic ulcer disease, 
the elderly and concomitant aspirin use (Sostres et 
al., 2010). Guidelines have therefore been devised in 
order to emphasise the importance of both risk factor 
modification when possible and more importantly, in 
considering alternatives to NSAID therapy and ensuring 
the proper prescription of gastroprotective agents when 
such therapy is required.
The guidelines used in this study as a standard 
on which questions and results were based were the 
National Institute for Health and Care Excellence 
(NICE) guidelines on NSAID Prescribing Issues 
last revised in July 2015 (NICE Guidelines NSAID 
Prescribing Issues, 2015).
The NICE guidelines currently recommend addition 
of a proton pump inhibitor (PPI) with all NSAIDs 
including COX-2 inhibitors based on two papers reporting 
three randomised controlled trials (RCTs) by Scheiman 
et al. (2006) and Chan et al. (2007).  Table 1 highlights 
the main recommendations in the NICE guidelines which 
this study aimed to explore.
OBJECTIVES
This study was designed to assess awareness of NICE 
guidelines on NSAID Prescribing Issues among general 
practitioners on proper NSAID prescription.  In light of 
these guidelines it specifically intended to address the 
following objectives:
•	 Assessment of the factors and medical issues 
considered by community doctors before initiating 
NSAIDs including knowledge of contraindications 
and drug interactions;
•	 To explore medical scenarios for which NSAIDs 
are used and patient age groups for which such 
medication is prescribed;
•	 To explore NSAID choices amongst general 
practitioners when NSAIDs are used;
•	 Assessment of NSAID side-effect monitoring within 
the community;
•	 Assessment of awareness amongst general 
practitioners (GPs) of which patients qualify as 
high risk;
•	 Assessment of co-prescription of gastroprotective 
agents by community doctors for high risk 
patient groups.
METHODOLOGY
Permission to carry out this study was obtained from the 
administration of the Primary Health Care Department 
prior to distributing an online questionnaire in September 
2016 to 139 doctors working in health centres across all 
regions in Malta. The data collected was then analysed in 
light of the NICE guidelines on NSAID prescribing issues 
last revised in July 2015.
Questions were aimed to assess awareness and 
practices amongst doctors working in the community 
and designed to address the objectives mentioned above.
RESULTS
The questionnaire was distributed to a total of 139 
doctors.  Fifty-six doctors participated in the study – four 
foundation trainees, eleven GP trainees and forty-one 
general practitioners giving a response rate of 40.3%.
The most common reasons for which NSAIDs are 
usually prescribed in general practice resulted to be 
trauma (75%), followed by chronic back pain (12.5%) 
and osteoarthritis (10.7%). When questioned about 
patient age groups for which NSAIDs are usually 
prescribed, 76.8% (43 doctors) answered that they 
prescribe NSAIDs to patients less than 45 years of age 
whilst 23.2% (13 doctors) answered that they mostly 
prescribe NSAIDs to patients between 45 and 64 years 
of age. There were no doctors who chose the 65 years + 
patient age group as their most common patient group 
to which they prescribe NSAIDs.
The doctors were also asked what factors they 
usually consider when initiating a patient on NSAIDs in 
their practice. Contraindications and drug interactions 
were the two most common factors considered, with 
dose and side effect monitoring resulting to be the 
least popular responses.  Figure 1 further demonstrates 
the results.
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Figure 1: Factors considered by GPs when initiating a patient on NSAIDs
Figure 2: Patient medical issues looked out for by GPs when considering NSAID use
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Figure 3: Awareness amongst GPs on NSAID interactions with medications frequently used in the community
The most popular type of NSAID used resulted to 
be diclofenac (55.4%) followed by COX-2 inhibitors 
(23.2%), ibuprofen (14.3%) and naproxen (7.1%).  This 
shows that standard NSAIDs are still the most popular 
choice at 76.8% versus COX-2 inhibitors at 23.2%.
Doctors were also asked whether they usually bring 
patients started on NSAIDs back for review of progress 
and to assess for continued need of NSAID use. 69.6% 
(39 doctors) replied that they review patients only in cases 
of no improvement or in cases of patients experiencing 
adverse events. 19.6% (11 doctors) responded that they 
do not review patients after NSAID initiation whilst 
10.7% (6 doctors) replied that they always review patients 
started on such treatment.
Figure 2 demonstrates patient medical issues usually 
looked out for by general practitioners when considering 
NSAIDs. Hypersensitivity, asthma and history of GI 
problems were the three commonest medical issues 
looked out for by community doctors when considering 
NSAID use with liver problems, fertility and dehydration 
amongst the least popular responses.
GPs were also questioned on awareness regarding 
drugs commonly encountered in primary care and their 
interactions with NSAIDs.  Anticoagulants were by far 
the most popular choice at 87.5%, unlike drugs such as 
diuretics, ciclosporin and probenecid that were amongst 
the least popular choices. Figure 3 further demonstrates 
these results.
87.5% of respondents perform blood pressure 
monitoring within their practice when monitoring for 
NSAID adverse effects. This was closely followed by 
monitoring for heart failure features at 82.1%.  Interesting 
to note was that only 5.4% include body weight assessment 
as part of their monitoring. Results are shown in Figure 4.
Figure 5 demonstrates data for scenarios in which 
doctors co-prescribe a gastroprotective agent when 
prescribing NSAIDs:
When asked regarding co-prescription of PPIs in high 
risk patients, 60.7% replied that they only co-prescribe 
a PPI when they use potent NSAIDs such as diclofenac. 
28.6% always prescribe a PPI irrespective of NSAID 
choice. 7.1% replied that they usually co-prescribe a PPI 
when they use ibuprofen whilst 3.6% advise a PPI when 
prescribing COX-2 inhibitors.
Study participants were also asked about regimes 
they use in their practice for gastroprotection when 
prescribing NSAIDs and results of their responses are 
demonstrated in Figure 6.
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figure 4: Parameters, investigations and examination findings used by gPs to assess for nsaid adverse events
Figure 5: Scenarios in which doctors co-prescribe a gastroprotective agent with NSAIDs
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DISCUSSION
The popularity of NSAID use within the community 
is undisputable as demonstrated by various studies 
performed throughout the years such as that by Bradbury 
in 2004 performed in Ireland, showing diclofenac, 
nimesulide and ibuprofen to make up 80% of total 
prescription issued by GPs (Bradbury, 2004).  Similar to 
the current study, an Italian study by Motola et al. in 2004 
showed that the main reasons for NSAID use within the 
community were osteoarticular pain (19%), unspecified 
pain (15%) and osteoarthrosis (9%). Given the usual 
chronicity of such scenarios, this further emphasises 
the importance of correct NSAID prescription including 
the identification of high risk groups to avoid potential 
adverse effects. It is also of note that in this study, 
diclofenac resulted to be the most popular choice (55.4%) 
despite its various documented side effects, with COX-
2 inhibitors being the preferred choice for only 23.2% 
of the GPs. This is in contrast to what seems to be the 
current situation within the UK as outlined by a clinical 
audit on NSAID safety performed across the UK in 2014 
demonstrating the most frequently prescribed agents to 
be naproxen (59%), ibuprofen (19%) and diclofenac at 
9% (NHS Specialist Pharmacy Services, 2014). Possible 
reasons for such a choice are many, including the fact 
that standard NSAIDs have been on the market for years 
and therefore clinicians might feel more comfortable with 
their use. It might also result from the fact that from 
past clinical experience, community doctors have found 
diclofenac to result in the highest patient satisfaction.
The NICE guidelines recommend using NSAIDs 
with caution in the elderly in view of an increased risk of 
serious adverse effects such as gastrointestinal bleeding 
and perforation which may be fatal. In this study, patient 
age groups for which NSAIDs are preferably prescribed 
resulted to be 76.8% for patients less than 45 years of 
age and 23.2% for patients between 45 and 64 years of 
age. There were rightly no responses for patients older 
than 65 years of age, reflecting the fact that patients 
older than 65 years are the patient group most likely to 
have multiple co-morbidities and therefore increased 
likelihood of contraindications, drug interactions and 
side effects.
The majority of GPs were aware of most of the 
factors that should be considered when initiating NSAID 
treatment as outlined in the NICE guidelines, with 
contraindications to NSAID use being the most popular 
factor (94.6%). Of note is that only 76.8% currently 
consider the use of gastroprotection especially in high risk 
patients. Moreover, whilst 76.8% of doctors stated that they 
take into consideration treatment duration, only 55.4% of 
doctors highlighted the need to consider the actual dose 
Figure 6: Regimes used by GPs for gastroprotection when prescribing NSAIDs
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used to address the medical problem in question. Possible 
reasons for this include that it might come as second 
nature to most GPs to start at the lowest possible dose 
when initiating treatment. It might also be due to the fact 
that community doctors might have their own preferred 
standard dose prescription which they have found most 
effective based on their past clinical experience.
It was also interesting to note that the least factor 
considered was side-effect monitoring, with only 50% 
of doctors highlighting the need to look out for possible 
medical reasons requiring closer monitoring for adverse 
effects. This fact was also brought out in other parts of 
the study namely when doctors were also asked whether 
they usually bring high risk patients started on NSAIDs 
back for review of progress and to assess for continued 
need of NSAID use. Whilst the majority of doctors 
(69.6%) replied that they usually review patients in cases 
of no improvement or in cases of patients experiencing 
adverse events, 19.6% responded that they do not review 
patients at all after NSAID initiation. This might reflect 
the fact that this study was distributed to community 
doctors working within government health centres which 
provides a walk-in service with duty allocation and thus 
makes such monitoring, patient review and follow up a 
challenge. This can encourage chronic NSAID use with 
a resulting increase in adverse side effects.
The majority of the GPs were able to mention most 
of the contraindications listed in the guidelines namely 
hypersensitivity (85.7%), asthma (96.4%), severe heart 
failure (73.2%), vascular disease including ischaemic 
heart disease, peripheral vascular disease, cerebrovascular 
disease at 67.9% and current treatment for gastrointestinal 
issues at 83.9%. However, a significant number of doctors 
failed to look out for severe skin reactions and angioedema 
(53.6%) which are listed as absolute contraindications 
within the guidelines, whilst the majority of GPs 
overlooked liver fibrosis and cirrhosis (23.2%), acute liver 
failure (21.4%) and severe hepatic impairment (33.9%). 
This might be due to the fact that, despite links between 
NSAID use and exacerbation of liver impairment being 
established, research is still ongoing on the subject, while 
acute symptomatic liver disease secondary to NSAID use 
is not a frequently encountered clinical problem when 
compared to respiratory and cardiovascular complications 
and therefore more awareness is required on the subject.
Although the level of risk of NSAIDs on conception is 
not yet known, the NICE guidelines recommend avoiding 
NSAID use based on advice from the Committee on Safety 
of Medicines (2006). In this study, only 26.8% of doctors 
mentioned using caution in women trying to conceive 
and giving due consideration of possible impairment 
of female fertility. This might be due to the fact that 
whilst adverse renal, cardiovascular and gastrointestinal 
complications are well known, potential for NSAIDs 
to adversely affect ovulation has received much less 
attention overall, even though this potential complication 
has been described in the medical literature for multiple 
decades. Moreover the actual level of risk on conception 
is still unknown, as no large-scale, prospective controlled 
trials have yet proven a link between female infertility and 
NSAID or COX-2 inhibitor use.
The online questionnaire distributed also aimed to 
explore further knowledge amongst GPs with regards to 
key drug interactions with NSAIDs mentioned within 
the guidelines, in primary care. The majority of GPs 
(87.5%) rightfully mentioned concomitant anticoagulant 
use such as warfarin as being a key interaction. However, 
only 51.8% of GPs considered low-dose aspirin to be a 
key interaction. Of note is also the fact that the majority 
failed to mention looking out for possible interactions 
with anti-hypertensives (responses ranging between 
44.6% for ACE inhibitors to 25% for loop diuretics) that 
might require dose adjustments of the anti-hypertensives 
or avoidance of concurrent use in certain cases (e.g. in 
cases of potassium-sparing diuretics). It also became 
evident that awareness on important interactions with 
drugs such as antidepressants, ciclosporin, methotrexate, 
quinolones and probenecid is also currently lacking. 
This emphasizes the importance of continued medical 
education and can be addressed in the form of evening 
medical updates outlining recently revised guidelines.
Whilst the majority of GPs successfully identified 
patients over 65 years of age and those with history of 
gastrointestinal (GI) problems as being patients at high 
risk of GI side effects thus requiring PPI prescription; 
the majority failed to identify hypertensives, people 
with chronic low back pain who are 45 years or older, 
patients with osteoarthritis or rheumatoid arthritis at 
any age and those with concomitant use of selective 
serotonin reuptake inhibitors (SSRIs). A study performed 
within GP practice in the UK by Hutchinson (2014) 
showed similar results. Moreover, awareness was also 
low for patients with cardiovascular, hepatic and renal 
impairment (17.9%), diabetics (19.6%), patients with 
concomitant aspirin and steroid use (41.1% and 58.9% 
respectively), patients with a history of heavy smoking or 
heavy alcohol use (26.8% and 41.1% respectively) and 
those with Helicobacter pylori infection (46.4%).
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Doctors were also asked on the need for co-
prescription of PPIs when prescribing different types of 
NSAIDs. The majority of GPs stated that they usually 
consider gastroprotection as an issue only when 
prescribing potent NSAIDs such as diclofenac (60.7%). 
Only 28.6% of GPs reported using gastroprotection with 
all kinds of NSAIDs used long term.
The NICE guidelines on NSAID prescription also 
describe specific licensed doses of proton pump inhibitors 
that should be used for gastroprotection for people who 
require continued NSAID treatment. Licensed PPIs and 
their doses mentioned in the guidelines include lansoprazole 
15-30mg daily, omeprazole 20mg daily (the choice of 46.4% 
of GPs in this study), esomeprazole 20mg daily (used by 
19.6% of GPs) and pantoprazole 20mg daily (used by 5.4% 
of GPs, though 3.6% reported also using a dose of 40mg of 
pantoprazole at occasions). Other responses in the study 
included use of omeprazole 40mg daily (19.6%) and of note 
was the fact that 3.6% of GPs chose ranitidine 150mg twice 
daily as their choice of gastroprotective agent, which is not 
licensed for gastroprotection during chronic NSAID use.
LIMITATIONS 
One limitation was the low response rate by GPs, the 
reasons for which could be various including lack of 
motivation and interest, the perception that participation 
may be time consuming and fear of lack of anonymity in 
the study with possible repercussions.
Results in this study were based on a questionnaire 
distributed amongst doctors working within the 
community and therefore only awareness of guidelines 
could be assessed. Data on actual implementation 
of such guidelines by GPs can only be gathered by 
assessing the actual practice records found within 
the various health centres for NSAID prescriptions. 
However, further addressing the objectives of this study 
by doing this was not possible in view of the high 
number and unpredictability of visits to the clinics, 
a lack of updated treatment records and furthermore, 
the lack of non-readily available lists of patient 
comorbidities within patient files. As a result, gathering 
information on treatment interactions and adverse effect 
monitoring was difficult. Participants’ recall bias could 
have also occurred.
CONCLUSION
This study showed that there is room for improvement 
in overall awareness on proper NSAID use and 
gastroprotection, identification of high risk patient 
groups, drug interactions and choice and dose of 
gastroprotective agents. It is evident that there is 
need for further awareness on the importance of 
gastroprotection, need for more frequent monitoring of 
patients to prevent unnecessary chronic NSAID use and 
promoting coxib use over standard NSAIDs especially 
in high risk patients groups.
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